Lipid level stabilization following combination therapy with IdaGlar and Semaglutide in type 2 diabetes: a...

To evaluate the clinical efficacy and lipid metabolism impact of intensified treatment with degludec-aspart dual insulin combined with semaglutide in patients with type 2 diabetes.

A systematic comparison and analysis were conducted on the changes in glycolipid metabolism-related indicators (including fasting blood glucose, glycated hemoglobin, fructosamine, and 2-hour postprandial blood glucose), blood glucose fluctuation indicators (specifically including standard deviation of blood glucose, postprandial blood glucose fluctuation amplitude, and 24-hour average blood glucose), insulin function status indicators (serum insulin level, fasting C-peptide (FCP), and 2-hour postprandial C-peptide (2hCP)), insulin resistance index, visceral fat index, and lipid index (including total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) between the two groups of patients. Additionally, the adverse reactions and their incidence rates during the treatment period were statistically analyzed.

Before treatment, there was no significant difference in glycolipid metabolism indicators, blood glucose fluctuation, insulin function and resistance index, visceral fat index, or lipid indicators between the two groups (all P > 0.05). After treatment, these indicators in both groups improved compared to before treatment, and the observation group showed significantly better outcomes than the control group (all P < 0.05). Moreover, there was no =significant difference in the incidence of adverse reactions between groups (P=0.576).

Intensified treatment with degludec-aspart dual insulin combined with semaglutide could improve blood glucose control, enhance insulin function, stabilize lipid levels, and did not increase treatment-related adverse reactions.